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ABStRAct
Copy‑number variants such as germ‑line deletions and amplifications are associated 
with inherited genetic disorders including familial cancer. The gene or genes responsible 
for the majority of familial clustering of pancreatic cancer have not been identified. 
We used representational oligonucleotide microarray analysis (ROMA) to characterize 
germ‑line copy number variants in 60 cancer patients from 57 familial pancreatic cancer 
kindreds. Fifty‑seven of the 60 patients had pancreatic cancer and three had nonpan‑
creatic cancers (breast, ovary, ovary). A familial pancreatic cancer kindred was defined 
as a kindred in which at least two first‑degree relatives have been diagnosed with 
pancreatic cancer. Copy‑number variants identified in 607 individuals without pancreatic 
cancer were excluded from further analysis. A total of 56 unique genomic regions with 
copy‑number variants not present in controls were identified, including 31 amplifications 
and 25 deletions. Two deleted regions were observed in two different patients, and one 
in three patients. The germ‑line amplifications had a mean size of 662 Kb, a median size 
of 379 Kb (range 8.2 Kb to 2.5 Mb) and included 425 known genes. Examples of genes 
included in the germ‑line amplifications include the MAFK, JunD and BIRC6 genes. The 
germ‑line deletions had a mean size of 375Kb, a median size 151 Kb (range 0.4 Kb 
to 2.3 Mb) and included 81 known genes. In multivariate analysis controlling for region 
size, deletions were 90% less likely to involve a gene than were duplications (p < 0.01). 
Examples of genes included in the germ‑line deletions include the FHIT, PDZRN3 and 
ANKRD3 genes. Selected deletions and amplifications were confirmed using real‑time 
PCR, including a germ‑line amplification on chromosome 19. These genetic copy‑number 
variants define potential candidate loci for the familial pancreatic cancer gene.
IntRoductIon
It has been estimated that 10% of pancreatic cancer has a familial basis.1-4 Members 
of kindreds in which one or more family members have been diagnosed with pancreatic 
cancer have a significantly increased risk of developing pancreatic cancer, and segregation 
analyses suggest that this aggregation is caused by the autosomal dominant inheritance of a 
rare allele.5-13 Several known inherited genetic alterations have already been identified that 
increase the risk of pancreatic cancer.11 These include inherited mutations in the BRCA2, 
BRCA1, STK11/LKB1, PRSS1 and p16/CDKN2A genes, and possibly in the PALLD 
gene.14-27 In total, however, these known genes account for <20% of the familial clus-
tering of pancreatic cancer. While linkage analyses would be a natural method to identify 
additional familial pancreatic cancer genes, the extremely high mortality rate of pancreatic 
cancer makes it very difficult to obtain germ-line DNA samples from multiple affected 
members of a kindred.28,29 We hypothesized that copy-number variants (CNVs) could 
be used to localize additional familial pancreatic cancer genes. CNVs have the advantage 
that they can be identified in single patients and CNVs have been associated with other 
forms of familial cancer.
CNVs in the human genome have recently been characterized using a variety of 
assays including representational oligonucleotide microarrays (ROMA), bacterial artifi-
cial chromosomes (BAC)-based array comparative genomic hybridization (CGH), single 
nucleotide polymorphism (SNP) genotyping and paired-end sequences.30-36 For example, 
three recent studies of CNVs using SNP genotyping data from the HapMap Consortium 
identified over 1000 deletions within the human genome.35-37 Most of these deletions 
involved known genes, and most of the deletions ranged in size from 500 bp to 10.5 
kb, but some reported germ-line deletions have been as large as 3 Mb.30,35-37 In one of 
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these analyses, Conrad et al. identified 92 genes that were entirely 
deleted in at least one of the 60 parent-offspring trios included in 
their SNP genotyping analyses.35 While these CNVs help define 
the full spectrum of human variation, they also provide a unique 
opportunity to identify disease causing genetic loci. For example, 
germ-line deletions were used by M. Fergusen-Smith to localize the 
red cell acid phosphatase gene to the short arm of chromosome 2, 
and by M. Mikkelson et al. to localize the Gc-locus to the long arm 
of chromosome 4.38,39
Although most familial syndromes appear to be caused by small 
intragenic mutations in cancer-associated genes, some familial 
syndromes are caused by larger germ-line deletions or duplications 
of these same genes.40-50 Large genomic deletions that inactivate 
the BRCA2 or BRCA1 genes have been identified in breast cancer 
families, 10% of APC gene mutation-negative (by the protein trun-
cation test) adenomatous polyposis families have a constitutional 
deletion of the entire APC gene, approximately 18% of patients 
with hereditary nonpolyposis colorectal cancer syndrome have 
large genomic deletions encompassing MLH1 or MSH2, and large 
germ-line deletions of mitochondrial complex II subunits SDHB and 
SDHD have been demonstrated in hereditary paraganglioma.40-43,47 
These findings suggest that the characterization of copy-number 
variants in cohorts of patients with familial cancer could help localize 
novel familial cancer genes. We therefore characterized the CNVs in 
a well-defined cohort of 60 cancer patients from familial pancreatic 
cancer kindreds using ROMA.
MEtHodS
This study was reviewed and approved by the institutional review 
board of The Johns Hopkins Medical Institutions (JHMI). Informed 
consent was obtained from study participants.
The National Familial Pancreas Tumor Registry (NFPTR) was 
founded at Johns Hopkins University in 1994. The NFPTR is one 
of the largest registries of familial pancreatic cancer in the world. 
Patients are recruited into this registry from two sources: (1) patients 
treated for pancreatic cancer at The Johns Hopkins Hospital are 
invited (either by an in-person visit or by mail) to participate, and 
(2) individuals with a personal or family history of pancreatic 
cancer can refer themselves through the Internet (pathology.jhu.
edu/pancreas) or they can be referred by a non-Hopkins health care 
provider. As of May 1, 2007, 2,339 families had enrolled in the 
NFPTR. These include 1,489 sporadic kindreds and 850 familial 
kindreds. Sporadic kindreds are defined as kindreds with at least one 
pancreatic cancer, but without a pair of first-degree relatives with 
pancreatic cancer.1 Familial kindreds are defined as kindreds in which 
a pair of first-degree relatives has been diagnosed with pancreatic 
cancer.1 A total of 191 familial kindreds in which a germ-line blood 
sample was available from at least one family member were eligible for 
inclusion in this study. Fifty-seven of these 191 familial kindreds were 
selected for inclusion in this study based on the availability of DNA 
samples. An individual with familial pancreatic cancer was included 
from 56 of the kindreds. A second patient with pancreatic cancer was 
included from one kindred so that we could test for transmission of 
the CNVs identified. Three individuals with nonpancreatic cancers 
(breast, ovary, ovary) who were genetically related (a mother and 
two were siblings) to a pancreatic cancer patient were also included. 
A total of 60 cases were therefore analyzed, and almost all were 
Caucasian. Epstein-Barr virus (EBV) transformed lymphoblastoid 
cells were used for the ROMA studies of the cases, and nontrans-
formed lymphocytes were used in the confirmations.
In addition to the 60 cases, ROMA data from a series of control 
individuals was used to identify common CNVs in the population. 
All individuals with known pancreatic cancer or predisposition to any 
known cancer were removed from the set leaving 372 individuals. Of 
these 372 individuals, 75% (282) were EBV transformed, allowing us 
to identify and control for possible abberations introduced by EBV 
transformation. Of these 372 individuals, one third were HapMap 
individuals who have varied origin. We also used normal genetic 
variation data from two publicly available datasets; one includes 
270 (non overlapping CEPH) individuals from four populations 
with ancestry in Europe, Africa or Asia, and the second utilizes 55 
unrelated individuals.32,51 When overlapping individuals were elimi-
nated, data from a total of 607 controls were included in the analyses. 
The inclusion of the CEPH individuals creates large diversity in the 
normal filter set which will be useful in identifying CNVs from a 
diverse population.
Supplies for ROMA. Enzymes BglII and T4 DNA ligase were 
supplied by New England Biolabs. Primers were supplied by Sigma 
Genosys. Cot1 DNA and tRNA were supplied by Invitrogen. The 
Megaprime labeling kit, Cy3-conjugated dCTP and Cy5-conjugated 
dCTP were supplied by Amersham-Bioscience. Taq polymerase 
[Eppendorf mastermix (2.5X)] was supplied by Eppendorf. Microcon 
YM-30 filters were supplied by Amicon, and formamide was supplied 
by Amresco. Phenol:chloroform was supplied by Sigma. NimbleGen 
photoprint arrays were synthesized by NimbleGen Systems Inc. 
Design of the ROMA array has been described previously (Ref. 52).
ROMA. Arrays were described previously (Ref. 52). In brief the 
arrays are based on representational techniques and thus all oligonu-
cleotides map to BglII fragments that are within the representations 
size range of 200–1000 bp. The array was designed to the June 2002 
build of the genome (NCBI Build 30) and the coordinates have 
been updated to the May 2004 build (NCBI Build 35). There are 
roughly 84,000 features on the array and these are scattered across 
the genome resulting in an average resolution of 30 kb. 500 ng of 
genomic DNA was used to prepare BglII representations (described 
previously in ref. 52). Minor changes in the protocol are as follows: 
as few as four 250-mL tubes were used for each sample for amplifica-
tion of the representation each with a 100 ml volume reaction. An 
equal number of tubes were used for reference for each sample that 
was coamplified. The cycle conditions were 95˚C for 1 min, 72˚C for 
3 min, for 20 cycles, followed by a 10-min extension at 72˚C. The 
contents of the tubes were pooled when completed. Representations 
were cleaned by phenol:chloroform extraction, precipitated, resus-
pended and the concentration determined. DNA was labeled as 
described with minor changes.52 Briefly, 2 mg of DNA template 
was placed (dissolved in TE at pH 8) in a 0.2-mL PCR tube. 5 mL 
of primers from the Amersham-Pharmacia Megaprime labeling kit 
were added and pipetted up and down several times. The volume 
was brought up to 50 mL with dH2O, and mixed. The tubes were 
placed in Tetrad at 100˚C for 5 min, then on ice for 5 min. To this 
was added 10 mL of labeling buffer from the Amersham-Pharmacia 
Megaprime labeling Kit, 5 mL of label (Cy3-dCTP or Cy5-dCTP), 
and 1 mL of NEB Klenow fragment. The tubes were placed in a 
Tetrad and incubate at 37˚C for 2 h. The labeled samples (Cy3 and 
Cy5) were combined into one Eppendorf tube, to which 50 mL of 
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1 mg/mL human Cot 1 DNA, 10 mL of 10 mg/mL yeast tRNA and 
200 mL of Low TE (3 mM Tris at pH 7.4, 0.2 mM EDTA) were 
added. This was then loaded into a Microcon Filter and centrifuged 
for 10 min at 12,600 relative centrifugal force (rcf ). The flowthrough 
was discarded and the sample then washed with 450 mL of Low TE. 
The sample was centrifuged at 12,600 rcf and the procedure repeated 
twice. The labeled sample was collected by inverting the Microcon 
column into a new tube and centrifuging for two minutes at 12,600 
rcf. The labeled sample was transferred to a 200-mL PCR tube and 
the volume adjusted to 5 mL of Low TE. Slides were prepared as in 
Lucito et al.52 with the following changes. The slides were washed 
briefly in milliQ H2O and dried with compressed nitrogen. The 
hybridization solution consisted of 50% formamide, 5X SSC and 
0.1%SDS. For each, 30 ml of hybridization solution was added to 
the 5 ml of labeled sample and mixed. Samples were denatured and 
hybridized as described earlier (ref. 52). For each sample two hybrid-
izations were performed in color reversal and the ratio from both 
experiments averaged to minimize dye specific variance. CNVs which 
appeared in only one experiment were ignored.
Filtering out CNVs seen in normals. The dataset if based on all 
probes would require a large data frame to represent all samples and 
would drastically slow down computing time. Much of the data from 
the genome represents nonevents or vast regions without CNVs. 
Therefore, the probe-based data was reduced to event-based data. 
In other words, only the CNVs, location and ratio, are represented 
in a file, thereby drastically reducing file size without decreasing the 
information content. This transformation was performed for both 
the familial pancreatic cancer and the normal filter sample datasets. 
The familial set was compared to the normal set to remove common 
CNVs. If a region altered in the familial set was found altered in the 
normal set, this region was removed from the familial set. In some 
instances the CNVs found in the familial set were larger than the 
CNV found in the normal individuals. In these cases the nonover-
lapping ends of the CNV were retained in final data set., If the non 
overlapping CNV was two probes or less the region was removed. We 
have allowed for some flexibility in the removal of CNVs from the 
familial set if found in the ROMA normal dataset of 372 individuals 
which is available as supplemental data. This flexibility allows the 
retention of CNVs that are found in below algorithmically defined 
percentages of individuals in the 372 normal filtration set. The data 
was processed three additional times such that a CNV identified in 
the familial samples was retained in the data set if it was found in less 
than 30%, less than 20%, less than 10% or not found in any of the 
372 normal individuals (the filtered dataset as well as the unfiltered 
full dataset are available at lucitolab.cshl.edu/rl_data.html). Python 
scripts were written to parse out information pertaining to the varia-
tions present only in familial pancreatic cancer patients and not in 
normal samples. There have been a number of papers which have 
identified CNVs in the normal population. We also used data avail-
able from two such publications to supplement our normal variation 
data.32,51 The CNVs identified in these studies were compared to 
the familial set of CNVs identified in the present study. If a CNV in 
the familial dataset overlapped a CNV reported in one of the control 
datasets, the CNV was removed from the familial dataset. For the 
remaining CNVs, regions were defined by the positions of the most 
upstream and downstream probes. The gene lists were then generated 
using the UCSC genome browser for the May 2004 Build. Genes 
that had any exons located within the boundaries specified by the 
most upstream and downstream probes were considered as candi-
dates and included in the catalog.
Confirmation of CNVs. Six CNV regions were selected for 
QPCR validation which contained or were relatively close to 
known oncogenes or tumor suppressors. In addition the regions 
were found on different chromosomes in different individuals. Two 
Taqman probe sets were designed for each region using Primer 
Express version 2.0. The nonfluorescent labeled oligonucleotides 
were tested on genomic DNA known to have two copies of the 
regions in question by standard PCR amplification, followed by 
testing on the same DNA with TaqMan assay and titrating DNA 
concentrations. TaqMan probes used in this study had to be sensitive 
enough to detect a two-fold difference in either direction which was 
tested by the above titration studies. After TaqMan probeset char-
acterization only three TaqMan pobesets were sensitive enough for 
further QPCR analysis; (Chromosome 2: 32,537,367–33,153,333, 
Chromosome 9: 19,426,668–20,442,925 and Chromosome 19: 
43,390,659–43,832,483). The TaqMan assay was performed in an 
ABI Prism 7900HT Sequence Detection System as follows: a master 
mix was made up of 10X Real-time PCR buffer, 50 mM MgCl2, 5 
mM dNTP mix w/ dUTP, Hot Goldstar Taq, Uracil N-Glycosylase 
(Eurogentec) and 10 mM each of Forward primer, Reverse primer 
and Taqman probe (Sigma-Genosys). Reactions were performed in a 
384-well clear optical reaction plate and each plate was covered with 
an optical adhesive cover (ABI Prism). The reaction conditions were 
as follows: 48˚C for 2 min, 95˚C for 10 min, 95˚C for 15 s, 60˚C for 
1 min, 72˚C for 30 s for 40 cycles. Similar analysis was performed for 
a large region of chr12p, but in this case the data was averaged over 
four probe sets evenly spaced across the proposed deletion. All other 
conditions were the same.
After testing the TaqMan probe sets the test DNAs were assayed 
as follows. The initial DNA assayed was from EBV immortalized 
lymphoblasts. Four DNAs were tested with the TaqMan probes, 
where only one was expected to contain a CNP for one of the 
regions. In addition the same control DNA mentioned above was 
also used as a template. Three dilutions of the DNA were made so 
that input template would be 10 ng, 4 ng and 0.4 ng. This increased 
the number of data points but also allowed the calculation of ampli-
fication efficiency. Each dilution was performed in triplicate and 
each run on the ABI Prism 7900HT Sequence Detection System was 
performed three times. Overall this yielded 18 data points to average 
for copy number as well as the two probe sets for each region.
Raw QPCR data was analyzed by SDS 2.1 software (ABI Prism) 
to give cycle threshold (Ct) values for each reaction. Ct values for 
each concentration of each DNA were averaged and compared to 
values for control genomic DNA using the equation:
DDCt = (Ct, target region - Ct, control region)c - (Ct, target 
region - Ct, control region)g
where c = the unknown sample (cell line genomic DNA) and 
g = the known sample (normal genomic DNA).53
The same QPCR assays were then repeated for nonimmortalized 
DNA for the regions that passed the first experiments (Chromosome 
2: 32,537,367–33,153,333, Chromosome 9: 19,426,668–20,442,925 
and Chromosome 19: 43,390,659–43,832,483). The results for 
these analyses were evaluated using the equation above.
Statistics. Summary statistics and logistic regression to compare 
deletions and amplifications was performed using STATA 9 software. 
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(StataCorp. 2005. Stata Statistical Software: Release 9.0. 
College Station TSC).
RESuLtS
Patients. The 60 cancer patients included in these 
analyses are summarized in Table 1. Briefly, their mean age 
was 66.75 years and 35 (61%) were male. Ten patients, 
including a sibling pair, came from families in which more 
than four members had been diagnosed with pancreatic 
cancer. In addition to the 57 patients with pancreatic 
cancer, three patients had extra-pancreatic malignancies 
(breast, ovary, ovary).
CNVs found only in cases. Fifty-six of the copy-number 
variants (CNVs) identified in the patients from the familial 
pancreatic cancer kindreds were not identified in any of the 
607 normal subjects (data for these CNVs, the entire unfil-
tered dataset as well as data obtained using more flexible 
constraints for filtering out common CNVs [see methods section] 
are available as supplemental data from the web lucitolab.cshl.
edu/rl_data.html) or the normal CNV data obtained from previous 
studies.32,51 These included 31 amplifications and 25 deletions. 
Additional data on these loci, including the genes within each CNV, 
are presented on the web (pathology2.jhu.edu/pancreas/roma.cfm) 
and as Supplemental Material.
The 31 germ-line amplifications had a mean size of 662 Kb, 
a median size of 379 Kb (range 8.2 Kb to 2.5 Mb). Twenty-nine 
(92.3%) of the 31 amplifications involved known genes. A total of 
425 genes were found within these amplifications (several examples 
of possible oncogenes given in Table 3, a complete list on the 
web: pathology2.jhu.edu/pancreas/roma.cfm) and as Supplemental 
Material. Some of the larger amplifications presumably represent 
amplifications that occurred in the process of transforming the 
lymphoblastoid cell lines. For example, some of the very large CNVs 
identified are likely not compatible with a normal phenotype and 
intellectual capacity. Indeed, we observed a large amplification of 
12p in a single transformed sample and this amplification could 
not be confirmed by quantitative PCR analysis of a nontransformed 
germ-line sample from the same patient (data not shown).
The 25 deletions had a mean size of 375 Kb, a median size 151 
Kb (range 0.4 Kb to 2.3 Mb) and included 81 known genes. Several 
examples of tumor suppressors given in Table 4, a complete list on the 
web: pathology2.jhu.edu/pancreas/roma.cfm and as Supplemental 
Material. Sixteen (64 %) of the 25 deletions involved genes. As was 
true for the amplifications, some of the larger deletions presumably 
represent deletions that occurred in the process of transforming the 
lymphoblastoid cell lines.
Transmission of the CNVs. Samples from multiple members of 
two kindreds were analyzed. Two members of one kindred and three 
members of a second kindred were included in the analyses. While 
the CNVs identified demonstrated familial transmission, the CNVs 
identified were found in the normal individuals as common CNVs 
in the general population. Thus, in this sampling of multiple family 
members we were not able to identify the transmission of a pancreatic 
cancer-specific CNV.
Known genes. In addition to the global approach taken to 
characterize the CNVs, we also looked at genetic loci known to 
harbor genes implicated in the development of sporadic and familial 
pancreatic cancer. These included: BRCA1, BRCA2, FHIT, STK11, 
p16/CDKN2A, TP53, SMAD4, KRAS and the recently described 
familial pancreatic cancer gene locus on chromosome 4q.26 The only 
change found in these genes was a deletion in the FHIT gene, but it 
was in a noncoding region.
Confirmation of selected CNVs. Six CNV regions detected by 
ROMA which contained or were relatively close to known onco-
genes, tumor suppressors or genes of interest were selected to validate 
that the CNVs were legitimate alterations in copy number by QPCR. 
After the QPCR probes were selected, three regions were evalu-
ated. These included the region on chromosome 2 containing copy 
number gain of the anti apoptotic gene BIRC6,54 the region on chro-
mosome 9, 1.3 Mb away from the INK/ARF locus, and the region on 
chromosome 19, 475 kb away from the PAK4 gene,55 a gene which 
can regulate anchorage independent growth when activated. For each 
region two sets of probes were designed, to ensure multiple probes 
within a region were in agreement. DNAs with identified lesions 
were assayed by QPCR and compared to DNAs which did not have 
corresponding lesions identified. These assays were first performed 
with DNA from EBV immortalized lymphoblasts since more mate-
rial was available. The regions that scored positive were then assayed 
on nonimmortalized DNA from the same patients. A total of 18 data 
points were averaged to determine the copy number in reference to 
two separate samples that did not have a CNP and the results are 
shown in Table 2. We can see that the QPCR assay accurately identi-
fies that one CNP as having four copies of DNA as compared to two 
copies in the reference sample.
Gene content of deletions and duplications. In univar-
iate analysis longer deletions/amplification were more likely to 
involve genes than shorter changes (p = 0.02), and deletions 
were less likely to involve genes than were amplifications (p < 
0.01). In multivariate analysis controlling for region size, dele-
tions were 90% less likely to involve a gene than were duplications 
(p < 0.01).
dIScuSSIon
The genetic basis for the clustering of pancreatic cancer is poorly 
understood.1 A handful of genes have been identified, but they 
account for only a minority of familial pancreatic cancer kindreds. 
Table 1	 Characteristics	of	the	60	patients
 number of  number of Patients  Age at diagnoses of  Gender of  
 Pancreatic  with Pancreatic  cancer in years  Patient  
 cancer Patients cancer Evaluated (Standard deviation) Evaluated 
 in Family
 2 16 pancreatic  67.9 (12.6) ) for  10 Male  
 3 Other  pancreatic  9 Female 
   52 (10) for other 
 3 17 65.2 (10.5) 9 Male  
    8 Female
 4 14 67.8 (9.8) 10 Male  
    4 Female
 More than 4 10 66.1 (11.1) 6 Male  
    4 Female
 Total 60 66.75 (10.9) 35 Male  
    25 Female
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Identifying the gene or genes responsible for the majority of 
familial pancreatic cancer would help guide genetic counseling56 
and early detection efforts,57-59 and it may form the basis for the 
development of future gene-specific thera-
pies.60,61 Unfortunately, the extremely high 
mortality rate of pancreatic cancer renders 
standard approaches for identifying familial 
cancer genes, such as linkage analysis, 
extremely difficult.28,29 Novel approaches to 
identify the gene or genes responsible for the 
familial clustering of pancreatic cancer are 
therefore needed. Ideally, these approaches 
would be applicable even when the only 
biospecimen available is a DNA sample from 
a single affected family member.
A growing body of evidence now makes it 
clear that copy-number variants (CNVs) are 
relatively common in the human genome.30 
CNVs can predispose to disease through a 
number of mechanisms.30 They can directly 
affect gene dosage, or may function in 
combination with other genetic and envi-
ronmental factors.30 In specific, germ-line 
deletions have been reported to cause a 
number of familial cancer syndromes.40-48 
These observations suggest that screening for CNVs should be an 
efficient way to identify loci that harbor the familial pancreatic 
cancer gene. We therefore applied ROMA to a well-characterized 
Table 2	 PCR	confirmation	of	selected	copy	number	variants
 CNV  Size of  Type of CNV QPCR  QPCR non  Copy  
 Coordinates CNV (bp)  Transformed Transformed Number
 Chromosome 2:     
 32,537,367‑ 615,966 Amplification ‑1.2 ‑1.1 4 
 33,153,333    
 Chromosome 9:      
 19,426,668‑ 1,016,257 Deletion 1.2 0.6 1 
 20,442,925     
 Chromosome 19:
 43,390,659‑ 441,824 Amplification ‑0.6 ‑0.5 3 
 43,832,483     
Table 2 shows the results of quantitative PCR (QPCR) for several CNVs identified in the familial samples. The first column defines the chromosome 
coordinates of the CNVs identified. The second column defines whether the CNV is deleted or duplicated. The third column (QPCR transformed) 
represents the difference in QPCR ct results for 18 replicates using EBV transformed DNA as a template. The fourth column (QPCR non trans-
formed) represents the difference in QPCR ct results for 18 replicates using non transformed DNA as a template. The fifth column (Copy Number) 
is an estimate based on normal having two copies of each allele. A negative signifies more copies of the DNA since PCR amplification in the test 
sample is faster. A positive value signifies less DNA in the test sample since amplification would take longer. A difference close to 0.5 would refer 
to half of the copies in normal which would be one copy. A value close to 1.0 would signify the same number as normal or two copies. A value 
of two would indicate two extra copies or four copies total.
Table 3	 Selected	germ‑line	duplications
Gene Location name Function
fancd2 chr3:9904280‑10967287 Fanconi anemia In response to DNA damage,  
   localizes to nuclear foci with  
   other proteins (BRCA1 AND  
   BRCA2) involved in  
   homology‑directed DNA repair.
mafk chr7:271085‑2158745 v‑maf musculoaponeurotic  transcription factor 
  fibrosarcoma oncogene homolog K 
rnd1 chr12:47458533‑47775626 Rho family GTPase 1 Member of the Rho GTPase  
   family, possibly, regulates the  
   organization of the actin  
   cytoskeleton in response to  
   extracellular growth factors
wnt10b chr12:47458533‑47775626 wingless‑type MMTV integration  These secreted proteins have  
  site family, member 10B been implicated in oncogenesis  
   and in several developmental processes
wnt1 chr12:47458533‑47775626 wingless‑type MMTV integration  These secreted proteins have been  
  site family, member 1 implicated in oncogenesis and in  
   several developmental processes
map2k2 chr19:2984601‑5201290 mitogen‑activated protein kinase kinase 2 The protein encoded by this gene is a  
   dual specificity protein kinase that  
   belongs to the MAP kinase kinase family.  
   This kinase is known to play a critical  
   role in mitogen growth factor signal  
   transduction. It phosphorylates and thus  
   activates MAPK1/ERK2 and MAPK2/ERK3.
jund chr19:17785312‑19480018 jun D proto‑oncogene A member of the JUN family, and a  
   functional component of the AP1  
   transcription factor complex. It has been  
   proposed to protect cells from p53‑ 
   dependent senescence and apoptosis.
For a complete listing of all duplications identified: pathology2.jhu.edu/pancreas/roma.cfm and as Supplemental Material.
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series of 60 cancer patients from 57 familial pancreatic cancer 
kindreds. Copy-number variants identified in 607 individuals without 
pancreatic cancer were excluded.
ROMA is an array-based CGH technology in which the complexity 
of the genetic material analyzed is reduced through a representative 
sampling of genetic fragments within a certain size-range.34,52 The 
reduced complexity obtained through the use of a representation 
reduces background noise.34,52 The ROMA arrays utilized in this 
study have >80,000 probes and an average resolution of 30 kb, and 
a number of phenotypically normal individuals have been analyzed 
using this technology providing a rich database of CNVs in the 
general population.34,52 ROMA has been used to identify CNVs 
in cancer as well as normal populations accurately.52 The only limi-
tation of ROMA presently is the resolution of the array used for 
detection and in the future we will be using arrays with up to 4 times 
the resolution of the current array.
In our analysis a series of 607 normal controls (372 from our own 
data and an additional 235 nonoverlapping normal controls from 
available public data) was used to exclude any CNVs prevalent in 
the general population.32,34,51 Of the 607 normals, 552 were CEPH 
members of varied heritage, creating a useful normal filter set for 
the varied heterogeneity that is often found in residents of America. 
In addition 372 of the control samples were from EBV transformed 
cells. If the normal filter set were separated into EBV and non EBV 
transformed samples, and then analyzed for deletions, the EBV 
transformed controls filtered out twice as many CNVs than did the 
non transformed counterparts. It appears that there are regions that 
are commonly altered by the immortalization. Thus, having the EBV 
transformed samples in the control filter set was useful in filtering 
out EBV transformation specific CNVs. Interestingly, the average 
number of copy gain CNVs were equal in the non transformed and 
EBV transformed samples in both the filter set and in the test set.
Thirty-one distinct loci of amplification were identified as were 
25 loci harboring deletions. The majority of these involved known 
genes (pathology2.jhu.edu/pancreas/roma.cfm and as Supplemental 
Material). Of interest, in multivariate analyses, after controlling 
for region size, deletions were 90% less likely to involve a known 
gene than were amplifications (p < 0.01), suggesting that germ-line 
deletions of a gene may be more deleterious than amplifications. 
Examples of a deletion and amplification were confirmed by quan-
titative PCR.
Functionally interesting candidate genes were selected from the 
CNV specific genes identified. Duplications are listed in Table 3. 
This list contains several genes whose duplication in the germ-line 
might be expected to contribute to the development of neoplasia. 
For example, a germ-line duplication of the JUND proto-oncogene 
on chromosome 19 was identified. JunD protects cells from p53- 
dependent senescence and apoptosis and JunD may protect cells 
from oxidative stress.62,63
Selected deletions are listed in Table 4. These deletions include, for 
example, the ANKRD3 gene on chromosome 21. The ANKRD3 gene 
codes for a protein involved in signal transduction through NFkB, 
it has been shown to be somatically deleted in sporadic pancreatic 
cancer,58 its expression is suppressed in prostate, liver, breast, head 
and neck squamous cell carcinoma, and melanoma.54,55
There are several limitations to our approach of using CNVs 
to localize the gene(s) responsible for the familial aggregation of 
pancreatic cancer. First, we used transformed samples as a source for 
the germ-line DNA, and the transformation process may introduce 
occasional genetic changes. We have used a large number of samples 
in the normal filtration set also transformed by EBV and thus more 
common alterations introduced in this process should have been 
removed. However, some of the very large CNVs identified are 
likely not compatible with a normal phenotype and intellectual 
capacity. Indeed, we observed a large multiple Mb amplification 
of 12p in a single transformed sample and this amplification could 
not be confirmed by quantitative PCR analysis of a nontransformed 
germ-line sample from the same patient (data not shown). Clearly, 
CNVs such as these should be confirmed in a nontransformed 
sample.
Second, CNVs are much more common than was originally 
thought.30,35-37 To date, over 1,000 CNVs have been described (refs. 
30 and 35–37). A CNV involving a gene in an individual does not 
prove that the CNV is the cause of the individual’s phenotype.30 
CNVs can only help localize candidate genes that then have to be 
confirmed, usually by sequencing additional affected and nonaffected 
individuals to determine if intragenic mutations in the gene cosegre-
gate with the disease, or by larger population-based studies.
In summary, we applied ROMA to a series of well-characterized 
patients with familial pancreatic cancer. A number of copy-number 
variants were identified that were not seen in a series of 607 controls. 
Many of these copy-number variants involved genes, and these genes 
can be prioritized in future attempts to localize the familial pancreatic 
cancer gene.
Table 4	 Selected	germ‑line	deletions
Gene Location name Function
FHIT chr3:60219748‑60263116 fragile histidine triad gene Member of the histidine triad gene family  
   involved in purine metabolism. Aberrant  
   transcripts from this gene have been  
   found in about half of all esophageal,  
   stomach, and colon carcinomas.
PDZRN3 chr3:73432926‑74029485 PDZ domain containing RING  This protein is found to be downregulated  
  finger 3 in gliomas
ANKRD3 chr21:39946855‑42268598 ankyrin repeat domain 3 A serine/threonine protein kinase that  
   interacts with protein kinase C‑delta. The  
   encoded protein can also activate NFkB.
For a complete listing of all deletions identified: http://pathology2.jhu.edu/pancreas/roma.cfm and as Supplemental Material.
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